Poster sessions

Oral posters

Aug. 31st
16:30

Poster session 1

SCREEN A
P11.3
16:30
Olufolakemi M. COLE
Soaps and cleansers and their association with atopic dermatitis severity in adolescents and adults in southwest Nigeria
P8.26
16:35
Erere OTROFANOWEI
The efficacy of an emollient/moisturiser in restoring hydration, skin pH and Trans Epidermal Water Loss (TEWL) in patients with Atopic Dermatitis
P13.1
16:40
Alpana MOHTA
Assessment of the Effects of a Colloidal Oatmeal-based Eczema Cream on Skin Microbiome and Barrier Function in Mild to Moderate Atopic Dermatitis: A Randomized Clinical Trial
P5.12
16:45
Magdalena BADZIĄG
Contact haptens in emollient products – an analysis of the Polish market
P10.20
16:50
Michele RAMIEN
Prescribing practices of Canadian clinicians for the treatment of moderate-to-severe atopic dermatitis (AD) in the pediatric population (<12 years old)
SCREEN B
P11.4
16:30
Kathrin THORMANN
Implementation and evaluation of a patient action plan for adult patients with atopic dermatitis
P10.21
16:35
Annice HERATIZADEH
Usefulness of the German S2k guideline’s checklist criteria for systemic therapy in patients with atopic dermatitis for routine care
P10.22
16:40
Alicja MESJASZ
Parental preferences regarding the novel systemic treatment for Atopic Dermatitis in children
P5.13
16:45
Rui CHEN
Assessing disease control in patients with atopic dermatitis by using the Atopic Dermatitis Control Tool (ADCT) in daily practice
P5.14
16:50
Junfen ZHANG
Validity, reliability, responsiveness, and interpretability of the Recap of atopic eczema (RECAP) questionnaire
SCREEN C
P5.15
16:30
Fandresena Arilala SENDRASOA
Treatment patterns of atopic dermatitis medication in children under 2 years of age in Antananarivo, Madagascar
P3.1
16:35
Raden Mohamad Rendy Ariezal EFFENDI
Atopic Dermatitis in Indonesian Children: A Case Control Study
P13.2
16:40
Ousmane FAYE on behalf of Mamadou GASSAMA
Severe atopic dermatitis treated with wet wrapping: a case reported to the dermatology hospital in Bamako Mali
P5.16
16:45
Muzna Khalfan MASOUD
Awareness, Attitude and Quality of Life among Primary Caregivers of Children with Atopic Dermatitis Attending the Regional Dermatology Training Center in Northern Tanzania in 2023
P2.1
16:50
Tae Woong SEUL
Drug survival analysis of dupilumab and associated predictors in patients with atopic dermatitis in South Korea: 4 years, single-center, retrospective study
SCREEN D
P2.2
16:30
Amina Nomtondo OUEDRAOGO
Is the Treatment of Atopic Dermatitis Related to Purchasing Power? Evidence From a Direct Medical Cost Evaluation in Ouagadougou?
P5.18
16:35
Junfen ZHANG
Limited health literacy and its associated health outcomes among adults with at least two atopic diseases
P9.14
16:40
Annika VOLKE
12 months prevalence of atopic dermatitis in resource rich countries: a systematic review and meta analysis
P8.27
16:45
Elise Josephina LEEMAN
Health literacy in patients with atopic dermatitis: a cross-sectional study in a tertiary referral centre
P5.17
16:50
Fandresena Arilala SENDRASOA
Pharmacists’ knowledge and practices about use of topical steroids in children with atopic dermatitis
 
Sept. 1st
10:00

Poster session 2

SCREEN A
P8.17
10:00
Rebecca POSPICH
The T cell response to staphylococcal serine-protease like protein in atopic dermatitis patients
P9.1
10:05
Nadia Oktafina PRAYITNO
A Multiplex Immunoassay for Simultaneous Detection of Antimicrobial Peptide in the Stratum Corneum of Atopic Dermatitis Skin
P8.13
10:10
Chang Ook PARK
Head and neck dermatitis is exacerbated by Malassezia furfur colonization, skin barrier disruption, and immune dysregulation
P8.15
10:15
Wanjin KIM
Microbiome analysis of bacteria and fungi in head and neck dermatitis in atopic dermatitis patients treated with dupilumab
P8.18
10:20
Yu Ri WOO
Increased expression of lipocalin correlates with disease activity of scalp dermatitis in patients with atopic dermatitis
P8.9
10:25
Jiehyun JEON
Serum level of Malassezia specific IgE antibody as a marker for severity of head and neck dermatitis in Korean atopic dermatitis patients
SCREEN B
P8.6
10:00
Krzysztof SITKO
Clinical significance of circulating heat shock proteins in patients with atopic dermatitis
P11.5
10:05
Anna ZARYCZAŃSKA
The expression of IL-19 and IL-37 in the skin of atopic dermatitis patients
P8.2
10:10
Alpana MOHTA
Periostin and Interleukin-13: Independent Associations with Atopic Dermatitis
P8.11
10:15
Arturo BORZUTZKY
Alterations of the CD200/CD200R immunomodulatory pathway in skin and blood from patients with atopic dermatitis
P8.10
10:20
Annie ZHANG
Dupilumab Treatment Normalizes Intraepidermal Nerve Fiber Density in Patients with Moderate-to-Severe Atopic Dermatitis and Improves Patient-Reported Outcomes
SCREEN C
P8.19
10:00
Macarena TEJOS-BRAVO
Effect of psychocosocial stress in patients with atopic dermatitis: relevance for somatosensory profile and small nerve fibers in chronic lesions
P8.14
10:05
Sun Hye SHIN
Identification of the impact of air pollutant-induced epigenetic changes on the development and exacerbation of atopic dermatitis
P8.20
10:10
Weronika ZYSK
The association between interleukin 35 gene single nucleotide polymorphisms and atopic dermatitis in the Polish population
P8.16
10:15
Sailan WANG
Exploring the role of the ADO gene in atopic dermatitis
P8.12
10:20
Isabel TAPIA-PAEZ
Searching for new candidate genes associated with Atopic Dermatitis in Ethiopians
SCREEN D
P8.1
10:00
Alpana MOHTA
Exploring the Role of Leptin in Atopic Dermatitis: Insights from a Study of School-Children in Western India
P8.5
10:05
Leszek BLICHARZ
Enterotoxin Gene Cluster and selX Are Associated with Atopic Dermatitis Severity-A Cross-Sectional Molecular Study of Staphylococcus aureus Superantigens
P8.7
10:10
Leszek BLICHARZ
Gut microbial dysbiosis is associated with intestinal barrier damage and IgE-mediated food allergy in adult patients with atopic dermatitis
P8.4
10:15
Yoonjin ROH
The alleviation of particulate matter-exacerbated atopic derma-titis via exosomes derived from adipose tissue-sourced mesen-chymal stem cells
P8.3
10:20
Argho Aninda PAUL
Ubiquitin proteasome system (UPS) mediated degradation of profilaggrin and alternation of degron route, ubiquitin conjugating amino acids and stability of pathogenic FLG mutant protein
 
Sept. 1st
15:30

Poster session 3

SCREEN A
P2.5
15:30
Alpana MOHTA
A case-control study of the assessment of COVID-19 severity in hospitalized children with atopic dermatitis
P2.6
15:35
Shruti CHOPRA
Identification and characterization of a novel possible genetic risk factor for eczema herpeticum
P2.7
15:40
Dorota JENEROWICZ
Pollen-food cross allergy in atopic dermatitis patients
P10.1
15:45
Alpana MOHTA
Sublingual Immunotherapy with Dermatophagoides Pteronyssinus (House Dust Mite) Extract for Atopic Dermatitis: A Placebo-Controlled Trial
P8.21
15:50
Hiroyuki MUROTA
Itch in atopic dermatitis is also induced by skin mobility by voluntary movement: lessons from a patient with amyotrophic lateral sclerosis
SCREEN B
P2.8
15:30
Fenohasina RAKOTONANDRASANA
Profile of comorbidities associated with atopic dermatitis at the department of dermatology in Antananarivo Madagascar
P2.9
15:35
Szymon MUĆKA
Characteristics of atopic dermatitis in patients over 60 years of age – a prospective single centre study
P2.10
15:40
Dong Hun LEE
Cardiovascular Disease-Specific Proteomics of Korean Patients with Atopic Dermatitis Reveal Distinct Proteomic Signatures
P2.11
15:45
Hae Chang JOH
Systemic lupus erythematosus accompanied with atopic dermatitis: A case series report
P2.12
15:50
Gloria Elisante MASENGA
Anxiety and Depression among Adult Atopic Dermatitis Patients Attending the Regional Dermatology Training Center in Northern Tanzania 2023
SCREEN C
P3.2
15:30
Anna ZARYCZAŃSKA
Allergic contact dermatitis in patients with atopic dermatitis
P4.1
15:35
Esmé KAMPHUIS
Efficacy and safety of dupilumab in patients with severe chronic hand eczema with inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled phase IIb proof-of-concept study
P5.2
15:40
Jiyoung AHN
Mycosis Fungoides Found in Patients with Atopic Dermatitis Refractory to Dupilumab; Newly Defined “Eczematous Mycosis Fungoides”
P2.13
15:45
Emilia MAJSIAK
Skin rash, atopic dermatitis, Duhring’s disease and celiac disease: can they coexist?
P8.8
15:50
Youin BAE
Clinical Implication of Serum Adiponectin Levels in Adult Patients with Atopic Dermatitis
SCREEN D
P5.1
15:30
Hyunchang KO
Prophylactic use of diquafosol eye drops for dupilumab-associated conjunctivitis in patients with severe atopic dermatitis: An open-label prospective study
P2.14
15:35
Sul Hee LEE
Ocular comorbidities of patients with atopic dermatitis in adolescent to young adults – a retrospective, single center study
P10.2
15:40
Aleksandra LESIAK
The use of methotrexate in atopic dermatitis in pediatric population-preliminary data from Systemic Treatment Efficacy In Atopic Dermatitis In Young Children And Adolescents (STEADY)
P12.1
15:45
Aleksandra LESIAK
Does serotonin give happiness to the skin? Preliminary study in atopic dermatitis patients
P2.15
15:50
Yu Ri WOO
Risk of developing hypertension in atopic dermatitis patients receiving long-term and low dose cyclosporine: A nationwide population-based cohort study
 
Sept. 2nd
10:00

Poster session 4

SCREEN A
P4.5
10:00
Andreas WOLLENBERG
Progressive and sustained disease control in patients with Atopic Dermatitis (AD) aged 12–17 years treated with tralokinumab for 52 weeks
P9.2
10:05
Mike BASTIAN
Dupilumab provides rapid improvements in signs, symptoms, and quality of life after the first dose
P10.9
10:10
Andreas WOLLENBERG
Evolution of EASI response with lebrikizumab in patients with moderate-to-severe atopic dermatitis: pooled results from two phase 3 trials (ADvocate1 and ADvocate2) at week 16
P10.11
10:15
Annie ZHANG
Long-Term Dupilumab Treatment is Not Associated With an Increased Overall Risk of Infections in Patients Aged 6 Months to 5 Years With Moderate-to-Severe Atopic Dermatitis in an Open-Label Extension Study
P10.12
10:20
Andreas WOLLENBERG
Long-term efficacy of tralokinumab in adolescents with moderate-to-severe atopic dermatitis
SCREEN B
P4.7
10:00
Peter NILSSON
Early Treatment Expectations with Abrocitinib Monotherapy: Week 4 Safety and Efficacy
P5.4
10:05
Jowita SROKA-TOMASZEWSKA
Result of treatment patients with atopic dermatitis – ineffectiveness dupilumab case series
P4.2
10:10
Anne Rosalie SCHLÖSSER
Upadacitinib treatment in a real-world difficult-to-treat atopic dermatitis patient cohort
P4.11
10:15
Alberto ALEGRE BAILO
Description of super-responders to tralokinumab treatment in atopic dermatitis: a multicenter study
P10.8
10:20
Annie ZHANG
Efficacy and Safety of Dupilumab Treatment up to 1 Year in Infants and Preschool Children With Moderate-to-Severe Atopic Dermatitis
SCREEN C
P10.7
10:00
Aleksandra LESIAK
Evaluation of the effectiveness and safety of the treatment with dupilumab in adult patients with severe atopic dermatitis in the B.124 program – the first real world evidence from one polish centre
P10.10
10:05
Marie Louise SCHUTTELAAR
Dupilumab treatment in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial
P5.3
10:10
Joo Yeon KO
Is elevated serum immunoglobulin E (IgE) level a marker of treatment failure of JAK inhibitor in atopic dermatitis? : A case report
P4.3
10:15
Sun Young CHOI
Effects of Oral Administration of Lactiplantibacillus Plantarum APsulloc 331261 Isolated from Green Tea on Atopic Dermatitis-like Skin Lesion Mouse Models
P10.4
10:20
Yi Na YOON
Polyarthralgia and Serum Sickness Following Dupilumab Treatment in a Patient with Atopic Dermatitis: A Case Report
SCREEN D
P10.6
10:00
Annie ZHANG
Dupilumab improves skin lipid composition in atopic dermatitis irrespective of patient filaggrin mutation status
P10.23
10:05
Magdalena TRZECIAK
The experiences from everyday life treatment of AD with Dupilumab – short time observation
P10.5
10:00
Yang Won LEE
Long-term efficacy and safety of dupilumab in real clinical practice : single center study
P4.6
10:15
Magdalena TRZECIAK
Temporal Response Patterns of Abrocitinib and Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of the JADE DARE Trial
P10.3
10:20
Jill OLYDAM
Effectiveness of abrocitinib treatment in patients with difficult-to-treat atopic dermatitis: daily practice data

Other posters

P1.1Weronika MATWIEJUK
Association Between Atopic Dermatitis and Epilepsy in Polish Population
P2.16Diana Libertad ORTEGA NÚÑEZ
Clinical characteristics of adult patients with severe atopic dermatitis in Mexico
P2.17Daud MANZAR
Safety and Efficacy of Nemolizumab for Pruritus: A Systematic Review and Meta-Analysis
P2.18Alpana MOHTA
Dermatitis Neglecta with atopic dermatitis- the menace of unwashed dermatosis in neglected children!
P4.8Annie ZHANG
Dupilumab improves skin lipid composition in atopic dermatitis irrespective of patient filaggrin mutation status
P4.9Jiayue ZHENG
Assessment of Upadacitinib\’s Impact on Immune Parameters in a Cohort of Atopic Dermatitis Patients Over Six Months
P4.10Jesse L. CARLIN
Itch and Sleep Improvements in a Pooled Analysis of Neurokinin-1 Receptor Antagonist Tradipitant in Atopic Dermatitis
P5.5Eleftheria TAMPOURATZI
Accelerated clinical improvement of atopic dermatitis under upatacitinib closely associated with serum biomarkers decrease
P5.6Henrik BRANDI
Additional costs related to oral Janus kinase inhibitor use in atopic dermatitis
P5.7Henrik BRANDI
Incremental risk of adverse events with oral Janus kinase inhibitor use in atopic dermatitis and other indications: a systematic review and meta-analysis
P5.8Dea METKO
Awareness of primary care providers about medical and mental health comorbidities, as well as the new advanced therapies for atopic dermatitis. A cross sectional survey from Ontario, Canada
P5.9Emmanuel SUNTRES
Prevalence of Creatine Phosphokinase Elevation in Patients receiving Immunomodulatory Therapies for Atopic Dermatitis: A Systematic Review and Meta-Analysis
P5.10Mckenzie VAN EATON
The Skin I’m In: associations of topical corticosteroid phobia in Canadian adults
P5.11Mari NAKANISHI
Possible effects of oral Janus kinase inhibitors for dupilumab facial redness
P5.19Alpana MOHTA
Comparison of ChatGPT and Dermatology Resident Performance in Dermatology Case Diagnosis
P5.20Alpana MOHTA
Evaluation of ChatGPT’s Ability in Basic Dermatology: A Comparative Study with Final-Year Medical Students
P8.22Alpana MOHTA
Investigating the Impact of Lactobacillus pentosus on Allergen-Sensitized Atopic Dermatitis in Children
P8.23Zafer E. OZTURK
Rapid and sustained improvement in sleep quality, anxiety, and depression in adults with moderate-to-severe atopic dermatitis with dupilumab treatment
P8.24Amalie Thorsti Møller RØNNSTAD
A randomized controlled study using oral dicloxacillin + mometasone furoate 0.1% vs. mometasone furoate 0.1% in adults with atopic dermatitis
P8.25Yu Ri WOO
The perturbed scalp skin microbiome in patients with atopic dermatitis
P9.3Jin Seon BANG
Validity and Reliability of Itch Intensity Scales for Chronic Pruritus in Atopic Dermatitis and Chronic Urticaria
P9.4Brian M. CALIMLIM
What Scores Correspond to Patient Satisfaction? Treatment Satisfaction Score Strata for Clinician- and Patient-Reported Outcome Measures in Atopic Dermatitis
P9.5Bark Lynn LEW
Drug survival analysis of dupilumab in moderate to severe atopic dermatitis patients: A retrospective study
P9.6Eung Ho CHOI
Diosmetin increases endogenous active glucocorticoid by activating local 11β-hydroxysteroid dehydrogenase type 1 and suppresses skin inflammation in a murine model of atopic dermatitis
P9.7Anne SOHRT PETERSEN
Matching-adjusted indirect comparison of the efficacy of tralokinumab and dupilumab in the treatment of moderate-to-severe atopic dermatitis beyond week 16
P9.8In Ho BAE / Chan Ho NA
The Atopic Dermatitis Control Tool to measure long-term control of atopic dermatitis in Korean patients undergoing dupilumab treatment: a retrospective single-centre analysis over 3 years
P9.9Malgorzata MAJ
Allergic contact dermatitis in patients with atopic dermatitis
P9.10Korey CAPOZZA
The Mental Health Burden of Atopic Dermatitis From an International Survey of Patients
P9.11Katharina ZEISER
Demographic encoded phenotypes in atopic dermatitis and related QoL- Cross sectional results from the ProRaD-study in 1011 patients
P9.12Klaudia SZYMCZAK
Antibacterial photodynamic inactivation as a tool to combat Staphylococcus aureus released from infected human keratinocytes – a simplified in vitro atopic dermatitis model
P9.13Magdalena TRZECIAK
Improvement of atopic dermatitis among Polish AD patients treated with mono- and complementary emollient plus therapy
P10.6Mette DELEURAN
Long-Term Safety Data for Dupilumab in a 5-Year Open-Label Extension Study of Adults With Moderate-to-Severe Atopic Dermatitis
P10.13Alpana MOHTA
Multistrain Synbiotic and Vitamin D3 Supplements for the Treatment of Atopic Dermatitis in Infants under One Year of Age: A Randomized, Double-Blind Clinical Trial
P10.14Jin Seon BANG
Variation in Hematological Parameters Associated with Janus Kinases 1 and 2 Inhibition in Two Patients
P10.15Annie ZHANG
Real-World Clinical Treatment Outcomes in Children < 12 Years of Age with Moderate-to-Severe AD: Interim Results From PEDISTAD Registry
P10.16Gaëlle BÉGO-LE-BAGOUSSE
Real-World Effectiveness of Dupilumab in Atopic Dermatitis – A Targeted Literature Review and Meta-Analysis
P10.17Andreas WOLLENBERG
Clinical response of lebrikizumab by disease duration: results from two phase 3 monotherapy studies
P10.18Brian M. CALIMLIM
Effect of Upadacitinib on intensity of scorad items and impacts to itch and sleep: analysis from the measure up 1 and measure up 2 studies
P10.19Tan NGUYEN
Pediatric atopic dermatitis patients’ experiences with dupilumab injections
P11.1Kim THOMAS
A new paradigm for conducting efficient, online eczema trials – the Rapid Eczema Trials project
P11.2Kim THOMAS
Implementing the Eczema Care Online behavioural intervention – key features and cost-effectiveness
P12.2Joanna NAKONIECZNA
Staphylococcus aureus from atopic dermatitis patients: similar or different?: characterization of genetic structure and susceptibility to killing by light-activated compound
P12.3Mendrika Fifaliana RAKOTOARISAONA
Follicular eczema associated with traditional therapy in a Malagasy child

Honour Patronages:


ISAD 2023